Fibroblast Activating Protein (FAP) PET/CT in Adults With Fibrotic Conditions
Abramson Cancer Center at Penn Medicine
Summary
This protocol is intended as a basket protocol designed to evaluate the use of Fibroblast Activating Protein (FAP) PET/CT in imaging the presence of fibrosis caused by a variety of medical conditions where fibrosis is believed to lead to pathological effects and poor prognosis.
Description
A study to evaluate subjects with fibrosis-inducing medical conditions that are known or suspected to cause tissue fibrosis (e.g. cancer-associated, post-infection, post-radiation, pre or post-transplant, cardiac, liver, kidney or pulmonary fibrosis). This protocol is intended to expand as needed with imaging arms designed to evaluate the use of Fibroblast Activating Protein (FAP) PET/ CT in imaging the presence fibrosis caused by medical conditions where fibrosis is believed to lead to pathological effects and poor prognosis. \[18F\]-FAPI-74 is a positron emitting radiolabeled FAP inhibitor…
Eligibility
- Age range
- 21+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria (by cohort) Head and Neck Cancer Cohort: 1. Participants will be ≥ 21 years of age 2. Diagnosis of oropharyngeal squamous cell carcinoma (OPSCC) 3. Determined to be surgical candidates 4. History of known or suspected fibrosis-inducing medical condition PTLD Cohort: 1. Participants will be ≥ 21 years of age 2. Diagnosed with microbiologically confirmed DS-pTB (culture or PCR positive) 3. History of known or suspected fibrosis-inducing medical condition. 4. Patient-reported completion of TB treatment within 2 years of enrollment. Cardiac Sarcoidosis Cohort: 1. Participa…
Interventions
- Drug[F-18]-FAPI-74
A positron-emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo expression of FAP with positron emission tomography (PET/CT).
Location
- University of PennsylvaniaPhiladelphia, Pennsylvania